Friday, 19 Jul 2019

You are here

IL-6 Blocker Succeeds in Real-World Vasculitis

Tocilizumab (Actemra) was effective for refractory giant cell arteritis (GCA) in real-world practice, although serious infections occurred relatively frequently, Spanish investigators reported.

Among a cohort of 134 patients treated in an open-label study, clinical improvements were seen in 93.9% after 1 month of treatment, according to Miguel A. González-Gay, MD, PhD, of Hospital Universitario Marqués de Valdecilla in Santander, and colleagues.

However, serious infections developed at a rate of 10.6/100 patient-years but were most common among patients receiving high doses of prednisone, the researchers reported online in Seminars in Arthritis & Rheumatism.

Conventional treatment for GCA, a large-vessel vasculitis that usually afflicts individuals over 50, is glucocorticoids, but adverse effects are common and relapses occur frequently following prednisone taper. The aorta and its major branches are most often affected, and blindness, stroke, and aneurysms can occur.

The cause of the disease is unknown, but proinflammatory cytokines such as tumor necrosis factor (TNF)-α and interleukin (IL)-6 have been implicated.

Multiple immunosuppressive agents as well as TNF inhibitors have been tried, but have shown little or no efficacy. However, two recent clinical trials reported beneficial results with tocilizumab and led to approval of this IL-6 receptor inhibitor for GCA in Europe and the U.S.

But in those trials, as is typical for randomized studies, many patients with comorbidities were excluded, patients with recent-onset disease were included, and follow-up was relatively brief.

Therefore, to evaluate the treatment in a real-life setting that included patients with refractory disease and comorbidities -- the patient population most likely to receive this treatment -- the investigators conducted an observational, retrospective study that included patients from 40 referral centers. All had previously received high-dose prednisone and almost three-quarters had also been given conventional or biologic immunosuppressives such as cyclophosphamide, hydroxychloroquine, abatacept (Orencia), infliximab (Remicade), or rituximab (Rituxan).

The diagnosis of GCA was confirmed with a positive biopsy of the temporal artery or using imaging techniques such as F-fluorodeoxyglucose PET scanning, MRI angiography, or CT angiography. For acute phase reactants, serum C-reactive protein (CRP) levels above 0.5 mg/dL and erythrocyte sedimentation rates (ESR) above 20 mm/hour in men and 25 mm/hour in women were considered abnormal.

Tocilizumab was given either intravenously, in dosages of 8 mg/kg every 4 weeks, or subcutaneously in a dosage of 162 mg/week, generally with background prednisone (40 to 60 mg/day), which was tapered gradually.

The study included 101 women and 33 men whose mean age was 73. Median disease duration was 13.5 months, and symptoms included headaches, constitutional symptoms such as anorexia and weight loss, jaw claudication, and visual abnormalities.

At month 1, median levels of CRP had declined from 1.7 to 0.11 mg/dL, ESR had fallen from 33 to 6 mm/hour, the percentage of patients with anemia had decreased from 16.4% to 3.8%, and mean hemoglobin levels had risen from 12.3 to 13.1 g/dL (P<0.0001 for all).

In addition, the median dosage of prednisone had already decreased from 15 to 13.75 mg/day (P<0.0001).

Clinical and laboratory improvements persisted throughout follow-up, which extended for up to 4 years, and among those followed for at least 2 years, persistent remission was seen in 39 patients (69.2%), with normal acute phase reactants and prednisone doses ranging from 0 to 5 mg/day.

Of those 39 patients, seven had mild relapses that were treated with small increases in the dose of prednisone.

After a median 12 months of follow-up, 32 patients (23.9%) reported an adverse event, with 17 necessitating discontinuation of treatment. The serious infection rate of 10.6/100 patient-years was higher than the 4.7/100 patient-years seen in a study of patients with rheumatoid arthritis treated with tocilizumab, González-Gay and co-authors noted.

Patients who had serious infections were somewhat older and had longer disease duration. Among patients receiving more than 15 mg/day of prednisone, the rate of serious infections was 16.3/100 patient-years compared with 4.2/100 patient-years among those with dosages below 15 mg/day.

"Taken together, our findings and the results of the randomized controlled trials [suggest that] tocilizumab seems to be an excellent therapeutic option in GCA" and "improves clinical manifestations, acute phase reactants, and imaging findings."

Limitations of the study, the researchers said, included its retrospective and observational design.

The authors reported financial relationships with AbbVie, Merck Sharp & Dohme, Roche, Pfizer, Eli Lilly, Sanofi, Bristol-Myers Squibb, and Janssen.

The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Rituximab Safety Concerns when Used in anti-TNF Refractory RA

The SUNSTONE study evaluated the long‐term safety of rituximab in rheumatoid arthritis (RA) previously exposed to ≥1 anti–tumor necrosis factor inhibitors (TNFi) and showed a stable, but high, rate of serious infections, opportunistic infections and an overall higher mortality rate.

No Difference Among Biologics in Arthroplasty Infectious Risk

A large administrative claims analysis of rheumatoid arthritis (RA) patients undergoing arthroplasty has shown no difference among biologics with regard to the risk of infections, but corticosteroid use was associated with a dose dependent risk of infection. 

The Annals of Internal Medicine has published an analysis of peri- and postoperative infectious risk among RA patients receiving biologics or glucocorticoids.

Is Methotrexate Necessary with Tofacitinib?

Rheumatoid arthritis patients taking tofacitinib (Xeljanz) plus methotrexate who achieved low disease activity (LDA) may be able to withdraw from the latter agent without significant worsening of disease activity, a researcher reported at EULAR 2019 in Madrid.

Upadacitinib Monotherapy in MTX-IR Rheumatoid Arthritis

Upadacitinib (UPA) is an oral, selective JAK1-selective inhibitor being developed for use in rheumatoid arthritis patients; Lancet has reported the SELECT-MONOTHERAPY trial showing that UPA is safe and effective in RA patients with an inadequate response to methotrexate (MTX).

This multicenter study randomized 648 patients, of whom 598 (92%) completed week 14.  

At week 14, an ACR20 responses were:

Predictors of Serious Infections with Rituximab

The risk of serious infectious events (SIE) with rituximab (RTX) is similar to that seen in other biologics (e.g., RA: 2% or 4.3/100PY), but with prolonged use the risk may change. Recent research says that low IgG levels, RTX induced neutropenia, prior SIE and comorbidities can significantly augment this risk. A retrospective longitudinal single center study of 700 rheumatic and musculoskeletal diseases (RMDs) treated monitored serum immunoglobulins (at baseline and 4–6 months after each cycle), clinical outcomes and SIE over time.